Voriconazole exposure and risk of cutaneous squamous cell carcinoma, Aspergillus colonization, invasive aspergillosis and death in lung transplant recipients

American Journal of Transplantation

Volumn 16, Issue 1, 2016, Pages 262-270

  Mansh, M ^a,b   Binstock, M ^a   Williams, K ^a   Hafeez, F ^a   Kim, J ^a   Glidden, D ^a   Boettger, R ^c   Hays, S ^a   Kukreja, J ^a   Golden, J ^a   Asgari, M M ^d   Chin Hong, P ^a   Singer, J P ^a   Arron, S T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DIVISION OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; VALGANCICLOVIR; VORICONAZOLE; ANTIFUNGAL AGENT;

ADULT; ARTICLE; ASPERGILLUS; DEATH; FEMALE; FUNGAL COLONIZATION; GRAFT RECIPIENT; HUMAN; INFECTION RISK; INVASIVE ASPERGILLOSIS; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; MORTALITY; PATIENT CARE; PHYSICIAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK BENEFIT ANALYSIS; RISK REDUCTION; SQUAMOUS CELL CARCINOMA; ADOLESCENT; ADVERSE EFFECTS; AGED; ASPERGILLOSIS; CARCINOMA, SQUAMOUS CELL; CHEMICALLY INDUCED; DRUG EFFECTS; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOCOMPROMISED PATIENT; MICROBIOLOGY; POSTOPERATIVE COMPLICATION; PROGNOSIS; RISK FACTOR; SKIN NEOPLASMS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOCOMPROMISED HOST; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SKIN NEOPLASMS; TRANSPLANT RECIPIENTS; VORICONAZOLE; YOUNG ADULT;

EID: 84956879493     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13431     Document Type: Article

References (44)

1. Berg D, Otley C., Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J Am Acad Dermatol 2002; 47: 1-17.
2. Sheil AG, Disney AP, Mathew TH, Amiss N., De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 1993; 25: 1383-1384.
3. Lindelof B, Jarnvik J, Ternesten-Bratel A, Granath F, Hedblad MA., Mortality and clinicopathological features of cutaneous squamous cell carcinoma in organ transplant recipients: A study of the Swedish cohort. Acta Derm Venereol 2006; 86: 219-222.
4. Ramsay HM, Fryer AA, Reece S, Smith AG, Harden PN., Clinical risk factors associated with nonmelanoma skin cancer in renal transplant recipients. Am J Kidney Dis 2000; 36: 167-174.
5. Roeger LS, Sheil AGR, Disney APS, Mathew TH, Amiss N., Risk factors associated with the development of squamous cell carcinomas in immunosuppressed renal transplant recipients. Clin Transplant 1992; 6: 202-216.
6. Jensen P, Hansen S, Moller B, et al., Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 1999; 40: 177-186.
7. Jensen P, Hansen S, Moller B, Leivestad T, Pfeffer P, Fauchald P., Are renal transplant recipients on CsA-based immunosuppressive regimens more likely to develop skin cancer than those on azathioprine and prednisolone? Transplant Proc 1999; 31: 1120.
8. Zwald FO, Brown M., Skin cancer in solid organ transplant recipients: Advances in therapy and management: Part 1. Epidemiology of skin cancer in solid organ transplant recipients. J Am Acad Dermatol 2011; 65: 253-261.
9. Sole A, Morant P, Salavert M, Peman J, Morales P., Aspergillus infections in lung transplant recipients: Risk factors and outcome. Clin Microbiol Infect 2005; 11: 359-365.
10. Husain S, Paterson D, Studer S, et al., Voriconazole prophylaxis in lung transplant recipients. Am J Transplant 2006; 6: 3008-3016.
11. Neoh CF, Snell GI, Kotsimbos T, et al., Antifungal prophylaxis in lung transplantation-a world-wide survey. Am J Transplant 2011; 11: 361-366.
12. Herbrecht R, Denning D, Patterson T, et al., Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-415.
13. Feist A, Lee R, Osborne S, Lane J, Yung G,. Increased incidence of cutaneous squamous cell carcinoma in lung transplant recipients taking long-term voriconazole. J Heart Lung Transplant 2012; 31: 1177-1181.
14. Vadnerkar A, Nguyen M, Mitsani D, et al., Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients. J Heart Lung Transplant 2010; 29: 1240-1244.
15. Zwald F, Spratt M, Lemos B, et al., Duration of voriconazole exposure: An independent risk factor for skin cancer after lung transplantation. Dermatol Surg 2012; 38: 1369-1374.
16. Singer J, Boker A, Metchnikoff C,. et al. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients. J Heart Lung Transplant 2012; 31: 694-699.
17. Voriconazole [package insert]. New York, NY: Pfizer, 2009.
18. Epaulard O, Villier C, Ravaud P, et al., A multistep voriconazole-related phototoxic pathway may lead to skin carcinoma: Results from a French nationwide study. Clin Infect Dis 2013; 57: e182-e 188.
19. Egan T, Murray S, Bustami R, et al., Development of the new Lung Allocation System in the United States. Am J Transplant 2006; 6: 1212-1227.
20. De Hertog S, Wensveen C, Bastiaens MT, et al., Relation between smoking and skin cancer. J Clin Oncol 2001; 19: 231-238.
21. Kotton C, Kumar D, Caliendo A, et al., Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 2013; 96: 333-360.
22. Wiita AP, Roubinian N, Khan Y, et al., Cytomegalovirus disease and infection in lung transplant recipients in the setting of planned indefinite valganciclovir prophylaxis. Transpl Infect Dis 2012; 4: 248-258.
23. Binder DA., Fitting Cox proportional hazards models from survey data. Biometrika 1992; 79: 139-147.
24. Lin DY., On fitting Cox's proportional hazards models to survey data. Biometrika 2000; 87: 37-47.
25. Vajdic CM, van Leeuwen MT,. Cancer incidence and risk factors after solid organ transplantation. Int J Cancer 2009; 125: 1747-1754.
26. Luong M, Chaparro C, Stephenson A, et al., Pretransplant aspergillus colonization of cystic fibrosis patients and the incidence of post-lung transplant invasive aspergillosis. Transplantation 2014; 97: 351-357.
27. Döring M, Blume O, Haufe S, et al., Comparison of itraconazole, voriconazole, and posaconazole as oral antifungal prophylaxis in pediatric patients following allogeneic hematopoietic stem cell transplantation. Eur J Clin Microbiol Infect Dis 2013; 33: 629-638.
28. O'Sullivan A, Pandya A, Papadopoulos G, et al., Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among neutropenic patients in the United States. Value Health. 2009; 12: 666-673
29. McLaughlin J, Equils O, Somerville K, et al., Risk-adjusted relationship between voriconazole utilization and non-melanoma skin cancer among lung and heart/lung transplant patients. Transplant Infect Dis 2013; 15: 329-343.
30. Gray D, Suman VJ, Su WP, Clay RP, Harmsen WS, Roenigk RK., Trends in the population-based incidence of squamous cell carcinoma of the skin first diagnosed between 1984 and 1992. Arch Dermatol 1997; 133: 735-740.
31. Armstrong B, Kricker A., The epidemiology of UV induced skin cancer. J Photochem Photobiol B 2001; 63: 8-18.
32. Weigt S, Elashoff RM, Huang C, et al., Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant 2009; 9: 1903-1911.
33. Cahill B, Hibbs JR, Savik K, et al., Aspergillus airway colonization and invasive disease after lung transplantation. Chest 1997; 112: 1160.
34. Felton T, Roberts S, Isalska B, et al., Isolation of Aspergillus species from the airway of lung transplant recipients is associated with excess mortality. J Infect 2012; 65: 350-356.
35. Garantziotis S, Palmer S., An unwelcome guest: Aspergillus colonization in lung transplantation and its association with bronchiolitis obliterans syndrome. Am J Transplant 2009; 9: 1705-1706.
36. Weigt S, Copeland C, Derhovanessian A, et al., Colonization with small Conidia Aspergillus species is associated with bronchiolitis obliterans syndrome: A two-center validation study. Am J Transplant 2013; 13: 919-927.
37. Singh N, Husain S., Aspergillosis in solid organ transplantation. Am J Transplant 2013; 13: 228-241.
38. Verleden G, Vos R, Verleden S, et al., Survival determinants in lung transplant patients with chronic allograft dysfunction. Transplantation 2011; 92: 703-708.
39. Clancy C, Nguyen M,. Long-term voriconazole and skin cancer: Is there cause for concern? Curr Infect Dis Rep 2011; 13: 536-543.
40. Bhaskaran A, Mumtaz K, Husain S., Anti-Aspergillus prophylaxis in lung transplantation: A systematic review and meta-analysis. Curr Infect Dis Rep 2013; 15: 514-525.
41. Schaenman J., Is universal antifungal prophylaxis mandatory in lung transplant patients? Curr Opin Infect Dis 2013; 26: 317-325.
42. Luong M, Hosseini-Moghaddam S, Singer L, et al., Risk factors for voriconazole hepatotoxicity at 12 weeks in lung transplant recipients. Am J Transplant 2012; 12: 1929-1935.
43. Doligalski C, Benedict K, Cleveland A, et al., Epidemiology of invasive mold infections in lung transplant recipients. Am J Transplant 2014; 14: 1328-1333.
44. Ong C, Keogh A, Kossard S, et al., Skin cancer in Australian heart transplant recipients. J Am Acad Dermatol 1999; 40: 27-34.